Michael Bennett

• 
  www.aacc.org/publications/cln/2009/september/Pages/Cove - [Cached Version]
  Published on: 9/1/2009    Last Visited: 9/19/2009  

  Bone markers are one such group of analytes the committee hopes to study in the future, according to Jones and Michael Bennett, PhD, committee chair and professor of pathology and laboratory medicine at University of Pennsylvania and director of metabolic disease laboratory at Children's Hospital of Philadelphia.
  ...
  Bennett added that standard intervals would eliminate much guesswork for labs. s for amino acids and steroid hormones, the AACC-proposed adjunct study could give the committee as much as 21 years of data, Bennett noted. "At the start of the study, the kids will be small babies, and there will be blood draws throughout these kids' childhoods," he explained. "This kind of material has thus far has been unavailable to children's hospitals," he added.
  ...
  Besides the sheer enormity of the NCS study sample, the AACC committee is excited at the prospect of accessing an overwhelmingly healthy population, Jones and Bennett emphasized.
  ...
  "It's very costly to recruit healthy individuals because there's a big ethics approval process," Bennett explained.
  ...
  Labs find values for children under age 3 particularly troublesome, Jones and Bennett agreed, because these children have a limited volume of blood.
  ...
  Bennett sees the AACC proposal as a win-win proposition with huge benefits, but emphasizes that even if NCS were to accept the proposal, both sides need to take several steps-including finalizing details, setting a budget, and securing funding-before the study starts. If AACC's proposal is accepted, its adjunct study could start sometime after the launch of the main study, currently anticipated in 2011.
  
  Bennett is both hopeful and wistful about the project. "If the proposal is accepted, it will provide a starting point to getting standards reference intervals for analytes in a pediatric population, for all ethnic groups, in both rural and urban areas," Bennett explained.

• 
  www.aacc.org/AACC/IndividualBiography.htm?NRMODE=Publis - [Cached Version]
  Published on: 12/16/2007    Last Visited: 12/16/2007  

  Michael J. Bennett, PhD
  
  Michael J. ( Mike) Bennett Ph.D., FRCPath, DABCC, FACB, is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and Director of the Metabolic Disease laboratory at The Children's Hospital of Philadelphia.He holds the Evelyn Willing Bromley Endowed Chair in Clinical Laboratories and Pathology at The Children's Hospital of Philadelphia.He obtained his Ph.D. at the University of Sheffield School of Medicine, UK and his training was with the Sheffield Central Hospitals Group and the Association of Clinical Biochemists (UK).A member of AACC since 1993, he has also been a member of the ACB since 1975.Mike was active with the Texas Section AACC, and served many roles on the committee including Chair, Nominating Committee Chair and Membership Chair.At the Division level, he is an active member of the Pediatric, Maternal Fetal Division where he has also served in numerous capacities on the Division Committee including Chair, Scientific Program Committee member and Chair, Nominating Committee member and Chair.He has served as a member of the Board of Directors of the NACB, a member of the NACB Education and Scientific Affairs Committee, and a member of the AACC Press Board of Directors.He is currently a member of the Board of directors of AACC and Chairs the NACB LMPG on follow up testing for expanded newborn screening for metabolic diseases by tandem mass spectrometry.He is Chairman of the Pediatric Reference Range Committee.Mike has received numerous awards including the Outstanding Clinical Chemist Award, Texas section AACC, the award for Outstanding Contributions to Pediatric Clinical Chemistry, Pediatric and Maternal-Fetal Division, the Distinguished Scientist Award of the NACB, and the AACC award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research.Mike has published over 240 peer-reviewed scientific papers, reviews and book chapters.He reviews manuscripts for more than thirty Medical and Scientific Journals and is currently on the editorial boards of Clinical Chemistry Journal (Reviews Editor), Molecular Genetics and Metabolism, Journal of Inherited Metabolic Diseases( Communicating Editor) and Annals of Clinical Biochemistry (Associate Editor).

• 
  www.aacc.org/EXPIRED/EN_Metabolic_Disease/Pages/default - [Cached Version]
  Published on: 10/23/2006    Last Visited: 1/17/2009  

  Michael J. Bennett, Ph.D., Chair

• 
  www.aacc.org/members/sycl/mentor/past_mentors/pages/def - [Cached Version]
  Published on: 10/23/2006    Last Visited: 3/31/2009  

  Michael J. Bennett Ph.D., FRCPath, DABCC, FACB

• 
  www.aacc.org/AACC/IndividualBiography.htm?NRMODE=Publis - [Cached Version]
  Published on: 10/30/2007    Last Visited: 10/30/2007  

  Michael J. Bennett, PhD
  
  Michael J. ( Mike) Bennett PhD, FRCPath, DABCC, FACB, is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and Director of the Metabolic Disease laboratory at The Children's Hospital of Philadelphia.He holds the Evelyn Willing Bromley Endowed Chair in Clinical Laboratories and Pathology at The Children's Hospital of Philadelphia.He obtained his Ph.D. at the University of Sheffield School of Medicine, UK and his training was with the Sheffield Central Hospitals Group and the Association of Clinical Biochemists (UK).A member of AACC since 1993, he has also been a member of the ACB since 1975.Mike was active with the Texas Section AACC, and served many roles on the committee including Chair, Nominating Committee Chair and Membership Chair.At the Division level, he is an active member of the Pediatric, Maternal Fetal Division where he has also served in numerous capacities on the Division Committee including Chair, Scientific Program Committee member and Chair, Nominating Committee member and Chair.He is presently a member of the Board of directors of NACB and a member of the NACB Education and Scientific Affairs Committee, and a member of the AACC Press Board of Directors.Mike has received numerous awards including the Outstanding Clinical Chemist Award, Texas section AACC, the award for Outstanding Contributions to Pediatric Clinical Chemistry, Pediatric and Maternal-Fetal Division, and the Distinguished Scientist Award of the NACB.Mike has published over 220 peer-reviewed scientific papers, reviews and book chapters.He reviews manuscripts for more than thirty Medical and Scientific Journals and is currently on the editorial boards of Clinical Chemistry Journal, Molecular Genetics and Metabolism, Journal of Inherited Metabolic Diseases and is an American Editor for Annals of Clinical Biochemistry.He sits on research grant review committees for the NIH, The American Heart Association and The United Mitochondrial Disease Foundation.

• 
  www.fonama.org/informazioni/esperti_umdf.html - [Cached Version]
  Published on: 2/4/2008    Last Visited: 3/8/2008  

  125 Malattia mitocondriale e distrofia muscolare Michael Bennett, PhD FRCPath DABCC
  ...
  73 Complesso IV, acido lattico e alanina Michael Bennett, PhD FRCPath DABCC

• 
  www.aacc.org/AACC/about/awards/hall_of_fame/Michael_Ben - [Cached Version]
  Published on: 10/23/2006    Last Visited: 9/12/2007  

  AACC > About AACC > Awards & Grants > Hall of Fame > Michael J. Bennett, PhD, FRCPath, DABCC, FACB
  ...
  Michael J. Bennett, PhD, FRCPath, DABCC, FACB
  ...
  Dr. Bennett is professor of pathology and laboratory medicine at the University of Pennsylvania and director of the metabolic disease laboratory at The Children's Hospital of Philadelphia.He also holds the Evelyn Willing Bromley Endowed Chair in Clinical Laboratories and Pathology at The Children's Hospital of Philadelphia.The main focus of Dr. Bennett's research has been the investigation of inborn errors of mitochondrial energy metabolism with a special emphasis on disorders of fatty acid metabolism.He was among the first to describe the fatal clinical phenotype and the first to identify neonatal metabolite abnormalities in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.These observations led to the expansion of newborn screening by tandem mass spectrometry, in which most newborns are now screened for MCAD deficiency and a number of other inborn errors of metabolism.He is currently studying the hyperinsulinism associated with deficiency of short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD), another enzyme of fatty acid oxidation.Dr. Bennett has also devoted 25 years to studying a group of untreatable and devastating inherited neurodegenerative diseases known collectively as Batten disease.He recently identified a novel anti-neuronal apoptosis pathway in one of these diseases, which may lead to the first rational therapeutic intervention.He has published more than 225 peer-reviewed scientific papers, reviews, and book chapters and has been involved with the organization of numerous national and international congresses.

• 
  www.aacc.org/AACC/IndividualBiography.htm?NRMODE=Publis - [Cached Version]
  Published on: 10/23/2006    Last Visited: 9/12/2007  

  Michael J. Bennett, PhD
  
  Michael J. ( Mike) Bennett PhD, FRCPath, DABCC, FACB, is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and Director of the Metabolic Disease laboratory at The Children's Hospital of Philadelphia.He holds the Evelyn Willing Bromley Endowed Chair in Clinical Laboratories and Pathology at The Children's Hospital of Philadelphia.He obtained his Ph.D. at the University of Sheffield School of Medicine, UK and his training was with the Sheffield Central Hospitals Group and the Association of Clinical Biochemists (UK).A member of AACC since 1993, he has also been a member of the ACB since 1975.Mike was active with the Texas Section AACC, and served many roles on the committee including Chair, Nominating Committee Chair and Membership Chair.At the Division level, he is an active member of the Pediatric, Maternal Fetal Division where he has also served in numerous capacities on the Division Committee including Chair, Scientific Program Committee member and Chair, Nominating Committee member and Chair.He is presently a member of the Board of directors of NACB and a member of the NACB Education and Scientific Affairs Committee, and a member of the AACC Press Board of Directors.Mike has received numerous awards including the Outstanding Clinical Chemist Award, Texas section AACC, the award for Outstanding Contributions to Pediatric Clinical Chemistry, Pediatric and Maternal-Fetal Division, and the Distinguished Scientist Award of the NACB.Mike has published over 220 peer-reviewed scientific papers, reviews and book chapters.He reviews manuscripts for more than thirty Medical and Scientific Journals and is currently on the editorial boards of Clinical Chemistry Journal, Molecular Genetics and Metabolism, Journal of Inherited Metabolic Diseases and is an American Editor for Annals of Clinical Biochemistry.He sits on research grant review committees for the NIH, The American Heart Association and The United Mitochondrial Disease Foundation.

• 
  www.waters.com/watersdivision/SiteSearch/search.asp?sea - [Cached Version]
  Published on: 3/11/2005    Last Visited: 10/26/2006  

  Type: Poster; Author: Scott Freeto, Donald Mason (Waters), Jie Chen, Robert Scott, Srinivas Narayan, and Michael Bennett (Children's Hospital of Philadelphia); Source: ASMS 2006 May 28-June 1 Seattle, Wa; AACC 2006, July 23-27, Chicago, IL; Year: 2006; Volume: 221; Page: 1 pp
  ...
  Type: Poster; Author: Scott Freeto, Donald Mason [Waters Corporation - Beverly, MA] Jie Chen, Robert Scott, Srinivas Narayan, Michael Bennett [Children's Hospital of Philadelphia - Philadelphia, PA]; Source: AACC 2006, July 23-27, Chicago, IL; Year: 2006; Page: 1 pp

• 
  9th International Congress on Neuronal Ceroid... - [Cached Version]
  Last Visited: 9/5/2006  

  Michael BennettUniversity of Texas Southwestern Medical School

Page:  1 2 3 4 5